Aptevo Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Aptevo Therapeutics Engages Piper Sandler to Sell its RUXIENCE(R) and IXINITY(R) Royalty Streams & Milestones

Lead Product(s): Rituximab

Therapeutic Area: Oncology Product Name: Ruxience

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Piper Sandler

Deal Size: $11.0 million Upfront Cash: Undisclosed

Deal Type: Divestment July 21, 2020

Details:

Aptevo is entitled to receive low single digit royalty payments from Pfizer Inc. pertaining to the net sales of RUXIENCE in the United States, European Union, and Japan. The royalty term runs for seven years, until early 2027, and payments are due quarterly.

Aptevo Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Aptevo Therapeutics to Receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimil

Lead Product(s): Rituximab

Therapeutic Area: Oncology Product Name: Ruxience

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Pfizer Inc

Deal Size: $0.7 million Upfront Cash: Undisclosed

Deal Type: Financing June 25, 2020

Details:

This collection relates to the Company's sale of its Hemophilia B therapy, IXINITY®, to Medexus Pharmaceuticals.

Aptevo Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Medexus Provides an Update on the IXINITY® Acquisition and its Overall Business in the COVID-19 Environment

Lead Product(s): Recombinant coagulation factor IX

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: MEDEXUS INC

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition May 22, 2020

Details:

The revenues from IXINITY® for March 2020 are in line with the Company’s expectations, including that the majority of the quarterly revenue from IXINITY® would be recognized in the final month of Q4 2020.

Aptevo Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial

Lead Product(s): APVO436

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 16, 2020

Details:

Dosing in cohorts 1 through 5 has been completed with dosing in cohort 6 scheduled to begin shortly.

Aptevo Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Medexus expands US product portfolio by acquiring hematology asset IXINITY

Lead Product(s): Recombinant coagulation factor IX

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: MEDEXUS INC

Deal Size: $30.0 million Upfront Cash: $30.0 million

Deal Type: Acquisition February 28, 2020

Details:

Acquisition strengthens Medexus’ specialty product portfolio and represents a strategic fit with other products in the Medexus business development pipeline.

Aptevo Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Aptevo Therapeutics' Apvo436 Selected For Inclusion In The Leukemia & Lymphoma Society's Groundbreaking Beat Aml(R) Master Clinical Trial

Lead Product(s): APVO436

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

APVO436 is a new investigational AML therapeutic, selected for an ongoing national AML master clinical trial spearheaded by The Leukemia & Lymphoma Society called the ‘Beat AML Master Clinical Trial.

Find

Find Clinical Drug Pipeline Developments & Deals by Aptevo Therapeutics

Pipeline Prospector Find Drug Development Pipeline & Deal Updates

Companies By Therapeutic Area

Development Status

Aptevo Therapeutics

Aptevo Therapeutics Engages Piper Sandler to Sell its RUXIENCE(R) and IXINITY(R) Royalty Streams & Milestones

Aptevo Therapeutics

Aptevo Therapeutics to Receive Seven Year Quarterly Royalty Payment Stream from Pfizer for Sales of Rituximab Biosimil

Aptevo Therapeutics

Medexus Provides an Update on the IXINITY® Acquisition and its Overall Business in the COVID-19 Environment

Aptevo Therapeutics

Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial

Aptevo Therapeutics

Medexus expands US product portfolio by acquiring hematology asset IXINITY

Aptevo Therapeutics

Aptevo Therapeutics' Apvo436 Selected For Inclusion In The Leukemia & Lymphoma Society's Groundbreaking Beat Aml(R) Master Clinical Trial